Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
Innovent Biologics, Inc.
CompanyAlso known as: Innovent, Innovent Biologics
Company Profile
Innovent Biologics is a publicly listed Chinese biopharmaceutical company headquartered in Suzhou, Jiangsu. Founded in 2011, it develops antibody and other biotech therapies and later listed on the Hong Kong Stock Exchange. Its ticker is 1801 on SEHK.
- Website
- https://www.innoventbio.com
- Headquarters
- Suzhou Industrial Park, Suzhou, Jiangsu, China
- Founded
- 2011
- Stock Ticker
- SEHK:1801
Related News
China Rises as Pharma R&D Powerhouse While India Pushes Innovation
China has become the dominant source of external drug innovation, with pharma licensing deals reaching $135.7 billion in 2025 and China developing 30% of the world's new innovative drugs. Meanwhile, India is expanding AI use in drug discovery and strengthening its CRDMO and IP infrastructure, though investment gaps persist.
Chinese Biotech Exports Surge to $137.7B as U.S. Drugmakers Rush to Acquire Chinese Candidates
China's biotech overseas technology transfer agreements reached $137.7 billion in 2025, nearly ten times the 2021 figure, as global drugmakers rush to acquire Chinese candidates. BeiGene's Brukinsa surpassed $4 billion in global sales, while Pfizer agreed to a deal with Innovent Biologics worth up to $10.5 billion. U.S. lawmakers are raising security concerns about growing dependence on Chinese biotech.
AstraZeneca nears pivotal data readout for sonesitatug vedotin in Claudin18.2 gastric cancer
AstraZeneca will report pivotal first-half data on sonesitatug vedotin in Claudin18.2 gastric cancer. The phase 3 Clarity-Gastric01 study is enrolling patients with ≥25% expression.
China's Regulatory Reforms Accelerate Biotech Innovation and Global Partnerships
China's regulatory reforms since 2015 have streamlined clinical trial and drug approval processes, accelerating development of advanced therapies like CAR-T and bispecific antibodies. These changes have boosted investor confidence and created opportunities for global pharmaceutical partnerships with Chinese biotech companies that have innovative pipelines but lack international marketing capabilities.
FDA Approves CAR-T Therapy for Marginal Zone Lymphoma, New Myeloma Drug Advances to Phase 2
The FDA has approved Bristol Myers Squibb's CAR-T therapy Breyanzi for relapsed/refractory marginal zone lymphoma, while a novel multiple myeloma drug candidate DTP3 advances to Phase 2 trials after showing promising early results. Both developments represent significant progress in blood cancer treatment, with the marginal zone lymphoma approval based on a 95.5% response rate and the myeloma drug demonstrating selective cancer cell killing without toxicity.
Multiple Myeloma Pipeline Expands With 80+ Therapies as Treatment Paradigms Evolve
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
Three Cancer Drug Trials Advance: AIM Plans Phase 3, Innovent Doses First Patient
AIM ImmunoTech partners with Thermo Fisher to design Phase 3 trial for Ampligen in pancreatic cancer, while Innovent Biologics begins dosing patients in Phase 3 study of IBI354 for HER2-positive breast cancer.
PD-1 and PD-L1 Inhibitors Market Expands with 200+ Drugs in Development Across 180+ Companies
A comprehensive market report reveals over 180 companies are developing more than 200 PD-1 and PD-L1 inhibitor drugs, with recent fast-track designations and successful Phase III trial results driving expansion in cancer immunotherapy.
Innovent Doses First Patient in Phase 3 Trial of IBI354 for HER2-Positive Breast Cancer
Innovent Biologics has dosed the first participant in its pivotal Phase 3 HeriCare-Breast01 study evaluating IBI354, a HER2-targeted antibody-drug conjugate, as first-line treatment for unresectable locally advanced or metastatic HER2-positive breast cancer.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07654062 |
Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07412262 |
A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and High Yes-associated Protein (YAP) Expression |
NOT_YET_RECRUITING | PHASE2 |
| NCT07342725 |
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07061535 |
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer |
RECRUITING | PHASE2 |
| NCT06936644 |
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation |
NOT_YET_RECRUITING | PHASE2 |
| NCT06292689 |
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer |
RECRUITING | PHASE2 |
| NCT06096909 |
Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population |
NOT_YET_RECRUITING | NA |
| NCT05843292 |
Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer |
NOT_YET_RECRUITING | PHASE4 |
| NCT05385809 |
A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer |
UNKNOWN | |
| NCT04371796 |
Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC |
UNKNOWN | PHASE2 |